Biomica, a subsidiary of Evogene, is an emerging biopharmaceutical company developing microbiome-based therapeutics utilizing a dedicated computational predictive biology platform.

Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings.

The company's initial focus is on the development of therapies for antibiotic-resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal disorders.